LongeVC’s Sergey Jakimov Featured in Axios Pro on Fund II Strategy
LongeVC managing partner Sergey Jakimov was featured in Axios Pro, discussing the firm's $120 million Fund II and biotech investment landscape. In the interview with Katherine Davis, Sergey shared insights on how NIH funding cuts create early-stage opportunities for savvy investors.
Sergey outlined LongeVC's pragmatic approach to longevity investing, focusing on age-related diseases with clear commercial pathways rather than speculative anti-aging hypotheses. He highlighted Fund I's strong performance, with over 3x returns and no write-offs.